Status:

ACTIVE_NOT_RECRUITING

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Haemophilia A Without Inhibitors

Haemophilia B Without Inhibitors

Eligibility:

MALE

12+ years

Phase:

PHASE3

Brief Summary

This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the ...

Eligibility Criteria

Inclusion

  • Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
  • Male aged 12 years or older at the time of signing informed consent.
  • Congenital severe haemophilia A (FVIII below 1%) or B (FIX equal to or below 2%).

Exclusion

  • Known or suspected hypersensitivity to any constituent of the trial product or related products.
  • Known inherited or acquired coagulation disorder other than congenital haemophilia.
  • Presence of confirmed inhibitors 0.6 BU or greater at screening.
  • History of thromboembolic disease (includes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion). Current clinical signs of, or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events.)

Key Trial Info

Start Date :

November 13 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 21 2028

Estimated Enrollment :

156 Patients enrolled

Trial Details

Trial ID

NCT04082429

Start Date

November 13 2019

End Date

February 21 2028

Last Update

December 5 2025

Active Locations (108)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 27 (108 locations)

1

Children's Hospital Los Angeles - Endocrinology

Los Angeles, California, United States, 90027

2

Center for Inherited Blood Disorders

Orange, California, United States, 92868

3

Center for Blood Disorders Augusta University

Augusta, Georgia, United States, 30912

4

Indiana Hemophilia-Thromb Ctr

Indianapolis, Indiana, United States, 46260